Vesicular stomatitis virus (VSV) therapy of tumors

被引:108
作者
Balachandran, S
Barber, GN
机构
[1] Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA
[2] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA
关键词
interferon; oncolytic virus; PKR; tumor; VSV;
D O I
10.1080/713803696
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vesicular stomatitis virus (VSV) is an essentially nonpathogenic negative-stranded RNA virus, the replication of which is extremely sensitive to the antiviral effects of interferon (IFN). We demonstrate here that VSV selectively induces the cytolysis of numerous transformed human cell lines in vitro, with all the morphological characteristics of apoptotic cell death. Importantly, VSV can also potently inhibit the growth of p53-null C6 glioblastoma tumors in vivo without infecting and replicating in normal tissue. With our previous findings demonstrating that primary cells containing the double-stranded RNA-activated protein kinase PKR and a functional IFN system are not permissive to VSV replication, these results suggest that signaling by IFN may be defective in many malignancies, Thus VSV might be useful in novel therapeutic strategies for targeting neoplastic disease.
引用
收藏
页码:135 / 138
页数:4
相关论文
共 18 条
  • [1] Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection
    Balachandran, S
    Roberts, PC
    Brown, LE
    Truong, H
    Pattnaik, AK
    Archer, DR
    Barber, GN
    [J]. IMMUNITY, 2000, 13 (01) : 129 - 141
  • [2] An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
    Bischoff, JR
    Kim, DH
    Williams, A
    Heise, C
    Horn, S
    Muna, M
    Ng, L
    Nye, JA
    SampsonJohannes, A
    Fattaey, A
    McCormick, F
    [J]. SCIENCE, 1996, 274 (5286) : 373 - 376
  • [3] Reovirus therapy of tumors with activated Ras pathway
    Coffey, MC
    Strong, JE
    Forsyth, PA
    Lee, PWK
    [J]. SCIENCE, 1998, 282 (5392) : 1332 - 1334
  • [4] Targeted disruption of the mouse STAT1 results in compromised innate immunity to viral disease
    Durbin, JE
    Hackenmiller, R
    Simon, MC
    Levy, DE
    [J]. CELL, 1996, 84 (03) : 443 - 450
  • [5] VESICULAR STOMATITIS-VIRUS INDIANA GLYCOPROTEIN AS A T-CELL-DEPENDENT AND T-CELL-INDEPENDENT ANTIGEN
    FREER, G
    BURKHART, C
    CIERNIK, I
    BACHMANN, MF
    HENGARTNER, H
    ZINKERNAGEL, RM
    [J]. JOURNAL OF VIROLOGY, 1994, 68 (06) : 3650 - 3655
  • [6] ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
    Heise, C
    SampsonJohannes, A
    Williams, A
    McCormick, F
    VonHoff, DD
    Kirn, DH
    [J]. NATURE MEDICINE, 1997, 3 (06) : 639 - 645
  • [7] Lee RK, 1999, CANCER RES, V59, P5514
  • [8] Targeted disruption of the STAT1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway
    Meraz, MA
    White, JM
    Sheehan, KCF
    Bach, EA
    Rodig, SJ
    Dighe, AS
    Kaplan, DH
    Riley, JK
    Greenlund, AC
    Campbell, D
    CarverMoore, K
    DuBois, RN
    Clark, R
    Aguet, M
    Schreiber, RD
    [J]. CELL, 1996, 84 (03) : 431 - 442
  • [9] FUNCTIONAL-ROLE OF TYPE-I AND TYPE-II INTERFERONS IN ANTIVIRAL DEFENSE
    MULLER, U
    STEINHOFF, U
    REIS, LFL
    HEMMI, S
    PAVLOVIC, J
    ZINKERNAGEL, RM
    AGUET, M
    [J]. SCIENCE, 1994, 264 (5167) : 1918 - 1921
  • [10] MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092